News
X4 Pharmaceuticals to Release Second Quarter 2024 Financial Results and Host Conference Call and Webcast on August 8, 2024
X4 Pharmaceuticals
BOSTON, July 30, 2024 (GLOBE NEWSWIRE) — X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a company focused on improving the lives of people with rare immune system diseases, today announced that it will release financial results for the second quarter ended June 30, 2024 and will provide a corporate update on Thursday, August 8, 2024.
The company will host a conference call and webcast on the same day at 8:30 a.m. ET. The conference call can be accessed by dialing 1-800-225-9448 from the United States or 1-203-518-9708 internationally, followed by the conference ID: X4PHARMA. The live webcast will be accessible through the investor relations section of X4 Pharmaceuticals’ website at www.x4pharma.com. After the call is completed, a replay of the webcast will be available on the website.
About X4 Pharmaceuticals
X4 is advancing progress for patients by developing and commercializing innovative therapies for those with rare immune system diseases and significant unmet needs. Leveraging our expertise in CXCR4 and immune system biology, we successfully developed mavorixafor, which has received U.S. approval as XOLREMDI™ (mavorixafor) capsules in its first indication. We are also evaluating the use of mavorixafor in additional potential indications. X4’s corporate headquarters are in Boston, Massachusetts, and our research center of excellence is in Vienna, Austria. For more information, please visit our website at www.x4pharma.com.
Company Contact:
Jose Juves
Head of Corporate and Patient Affairs
jose.juves@x4pharma.com
Contact the investor:
Daniel Balsa
Chief Executive Officer, LifeSci Advisors
daniel@lifesciadvisors.com
(617) 430-7576